2554 |
GAMMA-AMINOBUTYRIC ACID TYPE A RECEPTOR ALPHA1 SUBUNIT |
GABRA1 |
ECA4 |
EIEE19 |
EJM |
EJM5 |
137160 |
4075 |
ENSG00000022355 |
OTTHUMG00000163586 |
GABA(A) receptor subunit alpha-1 |
Gamma-aminobutyric acid receptor subunit alpha-1 |
P14867 |
GBRA1_HUMAN |
BE0008668 |
BE0000795 |
404 |
NP_000797 |
NM_000806 |
BE0004797 |
GAMMA-AMINOBUTYRIC-ACID RECEPTOR ALPHA-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14867] |
GABA<sub>A</sub> receptor α1 subunit |
GABRD |
PA28489 |
GABA(A) receptor alpha-1 |
T51487 |
gamma-aminobutyric acid type A receptor subunit alpha1 |
GuideToPharmacology Gene Category Name | GABA<sub>A</sub> receptors |
GuideToPharmacology Gene Category ID | 72 |
Human Readable Name | ION CHANNEL |
Interpro Short Name | Neur_chan_lig-bd |
Human Readable Name | DRUGGABLE GENOME |
Interpro Name | Neurotransmitter-gated ion-channel |
Interpro Acc | IPR006202 |
Interpro Name | Neurotransmitter-gated ion-channel ligand-binding |
Interpro Type | Domain |
Interpro Acc | IPR006201 |
Interpro Short Name | Neur_channel |
Uniprot Evidence | 1: Evidence at protein level |
Uniprot Status | Swiss-Prot |
Interpro Type | Family |
Target Subclass | Channels |
Target Subclass | Ligand_gated_ion_channels |
Target Subclass | cys-loop |
Target Main Class | Receptors |
Transmembrane Helix Count | 4 |
Target Class | Receptors |
Target Subclass | TC:1.A.9 |
Gene Biotype | PROTEIN_CODING |
ION CHANNEL |
DRUGGABLE GENOME |
positive modulator (activating) |
allosteric modulator |
Mechanism of Interaction | GABA receptor alpha-1 subunit positive allosteric modulator |
Direct Interaction | yes |
Trial Name | Indiplon |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator |
Trial Name | AZ-007, Staccato zaleplon |
agonist (activating) |
allosteric modulator |
potentiator |
Details of the Assay for Interaction | Assay using recombinant GABA<sub>A</sub> channels with subunit composition; α1β3γ2. |
Specific Action of the Ligand | Positive |
Endogenous Drug? | False |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
agonist (activating) |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
ligand |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | - |
ligand |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
ligand |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
ligand |
positive modulator (activating) |
allosteric modulator |
Specific Binding Site for Interaction | benzodiazepine site |
Details of the Assay for Interaction | Assay using recombinant GABA<sub>A</sub> channels with subunit composition; α1β3γ2. |
Specific Action of the Ligand | Positive |
positive modulator (activating) |
potentiator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Trial Name | Lunesta |
positive modulator (activating) |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel agonist |
Trial Name | - |
antagonist (inhibitory) |
blocker (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | None |
antagonist (inhibitory) |
Specific Binding Site for Interaction | GABA site |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
positive modulator (activating) |
allosteric modulator |
antagonist (inhibitory) |
Specific Binding Site for Interaction | benzodiazepine site |
Details of the Assay for Interaction | Affinity measured using α1β3γ2 receptors. |
Specific Action of the Ligand | Antagonist |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
ligand |
positive modulator (activating) |
Novel drug target | Established target |
Trial Name | Clobazam |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
ligand |
positive modulator (activating) |
allosteric modulator |
Trial Name | JZP-8 |
Novel drug target | Established target |
Details of the Assay for Interaction | Assay using recombinant GABA<sub>A</sub> channels with subunit composition; α1β1γ2. |
ligand |
positive modulator (activating) |
potentiator |
Novel drug target | Established target |
Trial Name | - |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
ligand |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator |
Direct Interaction | yes |
ligand |
positive modulator (activating) |
allosteric modulator |
potentiator |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Positive |
ligand |
positive modulator (activating) |
Trial Name | - |
Novel drug target | Established target |
Direct Interaction | yes |
ligand |
positive modulator (activating) |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
ligand |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
ligand |
positive modulator (activating) |
allosteric modulator |
potentiator |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | ARX-03, sufentanil + triazolam NanoTab |
ligand |
positive modulator (activating) |
allosteric modulator |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Specific Binding Site for Interaction | benzodiazepine site |
agonist (activating) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Full agonist |
allosteric modulator |
Specific Binding Site for Interaction | benzodiazepine site |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
positive modulator (activating) |
agonist (activating) |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
potentiator |
Trial Name | - |
Novel drug target | Established target |
n/a |
Trial Name | Ganaxolone |
Novel drug target | Established target |
positive modulator (activating) |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
Trial Name | topiramate controlled release,Trokesa |
positive modulator (activating) |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
Trial Name | - |
positive modulator (activating) |
potentiator |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
positive modulator (activating) |
Trial Name | - |
Novel drug target | Established target |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
Trial Name | - |
Novel drug target | Established target |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; agonist GABA site agonist |
Direct Interaction | yes |
Specific Binding Site for Interaction | GABA site |
positive modulator (activating) |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
allosteric modulator |
Specific Binding Site for Interaction | benzodiazepine site |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
partial agonist (activating) |
Trial Name | NG2-73 |
Novel drug target | Established target |
Direct Interaction | yes |
inverse agonist (inhibitory) |
Mechanism of Interaction | GABA-A receptor; benzodiazepine site inverse agonist |
Direct Interaction | yes |
allosteric modulator |
Trial Name | ocinaplon |
Novel drug target | Established target |
Specific Binding Site for Interaction | benzodiazepine site |
positive modulator (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; benzodiazepine site positive allosteric modulator |
antagonist (inhibitory) |
Specific Binding Site for Interaction | GABA site |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Binding Site for Interaction | GABA site |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel agonist |
Direct Interaction | yes |
positive modulator (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
positive modulator (activating) |
Direct Interaction | yes |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
positive modulator (activating) |
Mechanism of Interaction | GABA-A receptor; anion channel positive allosteric modulator |
Direct Interaction | yes |
n/a |
Trial Name | CNS-7056 |
Novel drug target | Established target |
n/a |
Mechanism of Interaction | GABA-A receptor; anion channel positive modulator |
Direct Interaction | yes |
GABRA1 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
GAMMA-AMINOBUTYRIC-ACID RECEPTOR ALPHA-1 SUBUNIT PRECURSOR (GABA(A) RECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P14867] | Description |
GABRA1 | Display Id |
ENSG00000022355 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
2554 | Entrez Gene Id |
GBRA1_HUMAN | Uniprot Id |
ENSG00000022355 | Ensembl Gene Id |
Target Subclass | Channels |
Target Subclass | Ligand_gated_ion_channels |
Target Subclass | cys-loop |
ENSG00000022355 | Ensembl Gene Id |
GAMMA-AMINOBUTYRIC ACID RECEPTOR SUBUNIT ALPHA-1 | Uniprot Protein Name |
2554 | Entrez Gene Id |
Human Readable Name | ION CHANNEL |
Interpro Short Name | Neur_chan_lig-bd |
Human Readable Name | DRUGGABLE GENOME |
ION CHANNEL, DRUGGABLE GENOME |
GABRA1 | Gene Symbol |
GABRD | Gene Symbol |
Target Class | Receptors |
Target Subclass | TC:1.A.9 |
4075 | HUGO Gene ID |
4075 | HUGO Gene Symbol |
gamma-aminobutyric acid type A receptor subunit alpha1 | HUGO Gene Name |
GuideToPharmacology Gene Category Name | GABA<sub>A</sub> receptors |
GuideToPharmacology Gene Category ID | 72 |
ION CHANNEL |
PA28489 | PharmGKB ID |
GABRA1 | DrugBank Gene Name |
P14867 | UniProt Accession |
2554 | Entrez Gene Id |
GABRA1 | DrugBank Gene Name |
P14867 | UniProt Accession |
2554 | Entrez Gene Id |
GABRA1 | DrugBank Gene Name |
P14867 | UniProt Accession |
2554 | Entrez Gene Id |
ENSG00000022355 | Gene Symbol |
GABRA1 | Ensembl Id |
DRUGGABLE GENOME |
GABRA1 | GENE_SYMBOL |
Gamma-aminobutyric acid receptor subunit alpha-1 | UNIPROT |
GABA(A) receptor subunit alpha-1 | UNIPROT |
Gamma-aminobutyric acid receptor subunit alpha-1 | Gene Name |
P14867 | UniProt ID |
ION CHANNEL |
GABRA1 | TTD Gene Abbreviation |
T51487 | TTD Target ID |